|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM33143055X |
| 003 |
DE-627 |
| 005 |
20231225213439.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202105711
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1104.xml
|
| 035 |
|
|
|a (DE-627)NLM33143055X
|
| 035 |
|
|
|a (NLM)34601753
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ji, Weihong
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Self-Catalytic Small Interfering RNA Nanocarriers for Synergistic Treatment of Neurodegenerative Diseases
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.03.2022
|
| 500 |
|
|
|a Date Revised 01.04.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2021 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Gene therapy has shown great potential for neurodegenerative diseases with complex pathology. However, its therapeutic effect is limited due to the delivery barriers and its own single function. Herein, self-catalytic small interfering RNA (siRNA) nanocarriers (S/Ce-PABMS) are developed to catalyze delivery process and treatment process for synergistic treatment of neurodegenerative diseases. On the one hand, the rough surface of the S/Ce-PABMS mediated by ceria (CeO2 ) nanozymes can catalyze cellular uptake in the delivery process, so that S/Ce-PABMS with acetylcholine analogs penetrate the blood-brain barrier and enter neurons more effectively. On the other hand, the CeO2 nanozymes can catalyze the treatment process by scavenging excess reactive oxygen species, and cooperate with siRNA-targeting SNCA to decrease the α-synuclein (α-syn) aggregation and alleviate the Parkinsonian pathology. Moreover, the S/Ce-PABMS treatment reduces the number of activated microglia and regulates the release of inflammatory cytokine, thereby relieving neuroinflammation. After treatment with S/Ce-PABMS, dyskinesia in Parkinson's disease model mice is significantly alleviated. The finding shows that the self-catalytic nanocarriers, S/Ce-PABMS, have great potential in the treatment of neurodegenerative diseases
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a brain delivery
|
| 650 |
|
4 |
|a nanozymes
|
| 650 |
|
4 |
|a neurodegenerative diseases
|
| 650 |
|
4 |
|a self-catalysis
|
| 650 |
|
4 |
|a siRNA
|
| 650 |
|
4 |
|a synergistic treatment
|
| 650 |
|
7 |
|a RNA, Small Interfering
|2 NLM
|
| 700 |
1 |
|
|a Li, Yan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Peng, Huan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Ruichen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shen, Jie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Yanyue
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Jianze
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hao, Qiulian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lu, Zhiguo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Jun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Xin
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 34(2022), 1 vom: 02. Jan., Seite e2105711
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:34
|g year:2022
|g number:1
|g day:02
|g month:01
|g pages:e2105711
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202105711
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 34
|j 2022
|e 1
|b 02
|c 01
|h e2105711
|